NCT04944173 2024-09-03
SCION
University of British Columbia
Phase 2 Withdrawn
Clinical Trials
6 trialsNCT05820763 2024-07-10
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
Phase 2 Withdrawn
NCT03982992 2024-03-12
DLI-TARGET
Ludwig-Maximilians - University of Munich
Phase 2 Withdrawn
NCT04029038 2023-08-21
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT04321577 2021-09-02
Validation of a Score That Predicts Residual Disease in Incidental Gallbladder Cancer
Hospital Universitari de Bellvitge
Withdrawn
NCT03699384 2019-02-20
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Withdrawn